H Ohta1, T Morita1, N Yokoyama1, T Osuga1, N Sasaki1, K Morishita2, K Nakamura2, M Takiguchi1. 1. Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan. 2. Veterinary Teaching Hospital, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo, 060-0818, Japan.
Abstract
OBJECTIVES: In this pilot study, serum canine pancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune-mediated diseases that were treated with immunosuppressive doses of prednisolone. METHODS: Ten client-owned dogs with newly diagnosed immune-mediated disease that had normal canine pancreatic lipase immunoreactivity concentrations (≤200 µg/l) were treated with 2 to 2.2 mg/kg prednisolone orally once daily as the initial treatment. Serum samples were obtained from each of the dogs prior to treatment and at 1- to 4-week intervals during immunosuppressive treatment. The highest canine pancreatic lipase immunoreactivity concentration detected during immunosuppressive treatment was defined as the peak canine pancreatic lipase immunoreactivity. RESULTS: Peak canine pancreatic lipase immunoreactivity concentrations were classified as normal in two dogs, questionable (201 to 399 µg/l) in three dogs, and abnormal (≥400 µg/l) in five dogs. Peak canine pancreatic lipase immunoreactivity concentrations were significantly higher than baseline canine pancreatic lipase immunoreactivity concentrations but there was no evidence of clinical pancreatitis. CLINICAL SIGNIFICANCE: It remains unclear whether the five of 10 dogs with elevated canine pancreatic lipase immunoreactivity during prednisone treatment had subclinical pancreatitis or whether the abnormal results were a consequence of prednisolone administration.
OBJECTIVES: In this pilot study, serum caninepancreatic lipase immunoreactivity was measured repeatedly in dogs with various immune-mediated diseases that were treated with immunosuppressive doses of prednisolone. METHODS: Ten client-owned dogs with newly diagnosed immune-mediated disease that had normal caninepancreatic lipase immunoreactivity concentrations (≤200 µg/l) were treated with 2 to 2.2 mg/kg prednisolone orally once daily as the initial treatment. Serum samples were obtained from each of the dogs prior to treatment and at 1- to 4-week intervals during immunosuppressive treatment. The highest caninepancreatic lipase immunoreactivity concentration detected during immunosuppressive treatment was defined as the peak caninepancreatic lipase immunoreactivity. RESULTS: Peak caninepancreatic lipase immunoreactivity concentrations were classified as normal in two dogs, questionable (201 to 399 µg/l) in three dogs, and abnormal (≥400 µg/l) in five dogs. Peak caninepancreatic lipase immunoreactivity concentrations were significantly higher than baseline caninepancreatic lipase immunoreactivity concentrations but there was no evidence of clinical pancreatitis. CLINICAL SIGNIFICANCE: It remains unclear whether the five of 10 dogs with elevated caninepancreatic lipase immunoreactivity during prednisone treatment had subclinical pancreatitis or whether the abnormal results were a consequence of prednisolone administration.
Authors: James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley Journal: J Vet Intern Med Date: 2019-03-07 Impact factor: 3.333
Authors: Julia K Prümmer; Judith Howard; Lisa M Grandt; Rafael Obrador de Aguilar; Felix Meneses; Laureen M Peters Journal: J Vet Intern Med Date: 2020-09-18 Impact factor: 3.333
Authors: Harry Cridge; David C Twedt; Angela J Marolf; Leslie C Sharkey; Jörg M Steiner Journal: J Vet Intern Med Date: 2021-11-09 Impact factor: 3.333
Authors: Beatriz Mendoza; Maria Joana Dias; Telmo Nunes; Maria Alexandra Basso; Juan Hernandez; Rodolfo Oliveira Leal Journal: J Vet Intern Med Date: 2020-11-04 Impact factor: 3.333